Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
Novartis receives first ever FDA approval for a CAR-T cell therapy
Novartis CAR-T Cell Therapy Receives FDA Approval for Third Indication ...
Novartis to cut 550 jobs in Switzerland to focus on cell therapy
Up to 120 jobs set to go as Novartis closes down Cell and Gene ...
Cell Therapy | Novartis
Novartis AG to Dissolve Cell and Gene Therapy Unit, Move Affects 400 ...
The FDA has approved our CAR-T cell therapy. Learn more:… | Novartis ...
Novartis sickle cell medicine Adakveo approved in Europe to prevent ...
Novartis scores its latest FDA OK — this time for a new sickle cell ...
Novartis signs $50 million deal for Mesoblast cell therapy for COVID ...
U.S. approves Novartis cell therapy for lymphoma | NAI 500
Watch: Novartis unveils new frontiers in cell and gene therapy at Expo ...
Novartis opens facility for innovative cell and gene therapies in ...
The Cell Cycle and Development 1st Edition Novartis Foundation | PDF ...
Novartis opens new cell and gene therapies facility in Switzerland
Novartis acting as cell therapy CDMO with Carisma - BioProcess Insider
Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble | Investor's ...
Novartis to cut 550 Swiss jobs, shifts focus to cell therapy
Novartis receives first ever FDA approval for a CAR-T cell therapy ...
Novartis CYStem Stem Cell and Gene Therapy Trial Is Moving Forward and ...
Réalisations, transport pneumatique - Novartis Cell for Cure
Novartis Opens €40M Viral Vector Facility in Slovenia to Boost Cell ...
Novartis to Launch New Cell Culture Manufacturing Line in Austria by Q3 ...
Swiss Novartis Opens Fastest Cell Culture Facility in Tyrol - Vindobona ...
Novartis Stein Cell and Gene Therapy Facility, Switzerland | Gene ...
Novartis says US regulator grants speedy review of CAR-T cell therapy ...
A short update from Novartis on Gene & Cell Therapies uptake | by Luca ...
Cell & Gene Therapy | Novartis Pharmaceutical Manufacturing Gm | CPHI ...
Continued Corporate Makeover: Novartis Disbands Cell & Gene Therapy ...
A, 914 cancer cell lines from the Novartis CLE were classified based on ...
Novartis Oncology on LinkedIn: Our BOLD approach to cell therapy
The Cell Cycle And Development 1st Novartis Foundation | PDF
Novartis' cell therapy ambitions outpace early returns | BioPharma Dive
Novartis Acquires Kate Therapeutics for $1.1 Billion • CHEManager is ...
Medicines: UK's MHRA revokes authorisation for Novartis' sickle cell ...
Novartis' Cell & Gene Therapy Storyline Deck | Behance
T-Cell arrival at the Novartis manufacturing facility | Novartis
Novartis logo on the Banting 1 building, Novartis Campus Basel ...
Cosentyx Becomes First Novartis Medicine Offered at 55% Discount ...
Novartis scores FDA approval for new version of SMA gene therapy
Novartis plots Precision attack on sickle cell, paying $75M and putting ...
Novartis Unveils Groundbreaking Gene Therapy Facility - The Region
Novartis Job Cuts: Novartis to Cut 550 Jobs in Switzerland Amid Shift ...
Novartis sickle-cell drug gets US FDA approval - Business & Finance ...
EMA CHMP recommends Novartis’ Tabrecta for non-small cell lung cancer
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self ...
Novartis to buy France's CellforCure to boost cell, gene therapy ...
Novartis, Precision Ink Deal to Develop Potential Sickle Cell Cure ...
Novartis buys another 2.5 pct in Israel's Gamida Cell, Health News, ET ...
Novartis investigational therapy crizanlizumab (SEG101) receives FDA ...
FDA starts speedy review of Novartis’ sickle cell antibody - PMLiVE
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA
Excellergy to be acquired by Novartis for up to USD 2 billion to ...
FDA approves Novartis Kesimpta® (ofatumumab), the first and
PPT - Licensing Pandemic Vaccines Novartis Vaccines PowerPoint ...
EU pulls authorization of Novartis’ sickle cell disease drug - PharmaLive
FDA Grants Priority Review to Novartis's CAR-T Cell Therapy - Drug ...
Novartis’s big bet on sickle cell disease struggles to reach Kenya ...
Novartis Receives EU Approval for First-Line Use of Zykadia ...
Novartis Bolsters Retinal Gene Therapy Position with Gyroscope ...
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in ...
Novartis announces partnership with the American Society of Hematology ...
Novartis signs $1.1B deal for muscular dystrophy biotech
Novartis Novartis Hi Res Stock Photography And Images Alamy
Novartis' ceritinib improves survival in patients with non-small cell ...
Por dentro da Novartis | novartis
AZ makes another cell therapy play with $1.2bn Gracell buy | pharmaphorum
Novartis Drug Cosentyx: Novartis' Cosentyx Drug Fails to Treat Giant ...
How the Dynamic Dance of Teamwork Makes CAR-T Cell Therapy Possible ...
Novartis Annual Report 2025 | Novartis
Stefan Hendriks - Novartis Oncology
Broad-Novartis Cancer Cell Line Encyclopedia database analysis for mRNA ...
Partnering | Novartis
Novartis Oncology Logo
Novartis' shift to superpricey cell and gene therapies draws investor ...
Raising awareness of Sickle Cell disease - Euronews
Novartis India shares surge most in over six years on this important ...
Cell gene therapy hi-res stock photography and images - Alamy
Novartis collaborates with Dren Bio to discover and advance novel ...
Acute monoblastic/monocytic leukaemia - CELL - Atlas of Haematological ...
32 Novartis Vaccines North America Stock Photos, High-Res Pictures, and ...
ASH 2017: Novartis Presents Data for Serious Blood Disorders like ...
Novartis is set to expand its radiopharmaceutical portfolio - M&A ...
LFB cède CellforCure à Novartis - Capital Finance
Turning Cell Division Research into Breakthrough Medicine
Introduction - CELL - Atlas of Haematological Cytology
Breakthrough in immunotherapy: Novartis receives first ever FDA ...
U.S. approves new drug to manage sickle cell disease, costs $85,000 to ...
Novartis Names Sandoz Board Members Ahead of Spin-Off
Novartis on LinkedIn: Novartis inaugurated a new manufacturing facility ...
Novartis shifts focus as CAR T-cell therapy fails to add benefit in non ...
EU regulator recommends revoking authorisation for Novartis' sickle ...
US FDA approves Novartis' gene therapy for rare muscle disorder - The ...
Novartis’ Ianalumab Earns FDA Breakthrough Status in Sjögren’s Disease ...
FDA approves gene therapy for rare muscle disorder | | azdailysun.com
Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous ...
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH | pharmaphorum
Can Artificial Intelligence Invent Things? A Curious Legal Case Could ...
Treatments for blood cancers and serious blood disorders are advancing ...
FDA advisory committee recommends approval of T-cell 'living drug' to ...
